glp 1 and cholesterol Mechanism by which excessive circulating levels of GLP-1 may lead to Potential of Glucagon-Like Peptide 1
Description
2012 Wolfe RR et al
Asia Pacific is emerging as the fastest-growing region, driven by rising rates of type 2 diabetes, urban obesity, and expanding healthcare access
A massive adoption of GLP-1 drugs in leading markets and growth areas (notably Asian markets) could be a significant blow to many food companies
This medication can also help lower the risk of cardiovascular events like stroke or heart attack in people with type 2 diabetes and heart disease
